Should doctors, patients, and policymakers have complete information about new drugs? Complete transparency may seem like the obvious answer. But the reality is that available information is often incomplete.
Article
Avoiding the TRIPS Trap: A Path to Domestic Disclosure of Clinical Drug Data Consistent with International Norms, Vol. 54
6 Nov 2023